Docality.com Logo
 
Dr. Khalid  Malik  Md image

Dr. Khalid Malik Md

251 E Huron St Feinberg 5-520
Chicago IL 60611
312 268-8369
Medical School: Other - 1985
Accepts Medicare: Yes
Participates In eRX: Yes
Participates In PQRS: Yes
Participates In EHR: Yes
License #: 036089578
NPI: 1881684231
Taxonomy Codes:
207LP2900X

Request Appointment Information

Awards & Recognitions

About Us

Practice Philosophy

Conditions

Dr. Khalid Malik is associated with these group practices

Procedure Pricing

HCPCS Code Description Average Price Average Price
Allowed By Medicare
HCPCS Code:64483 Description:Inj foramen epidural l/s Average Price:$1,832.00 Average Price Allowed
By Medicare:
$263.04
HCPCS Code:62310 Description:Inject spine c/t Average Price:$1,302.00 Average Price Allowed
By Medicare:
$263.58
HCPCS Code:62311 Description:Inject spine l/s (cd) Average Price:$1,228.00 Average Price Allowed
By Medicare:
$222.74
HCPCS Code:64448 Description:N block inj fem cont inf Average Price:$803.00 Average Price Allowed
By Medicare:
$62.53
HCPCS Code:64445 Description:N block inj sciatic sng Average Price:$808.00 Average Price Allowed
By Medicare:
$82.52
HCPCS Code:99291 Description:Critical care first hour Average Price:$678.00 Average Price Allowed
By Medicare:
$236.89
HCPCS Code:77003 Description:Fluoroguide for spine inject Average Price:$412.00 Average Price Allowed
By Medicare:
$61.37
HCPCS Code:00410 Description:Anesth correct heart rhythm Average Price:$445.89 Average Price Allowed
By Medicare:
$131.98
HCPCS Code:20610 Description:Drain/inject joint/bursa Average Price:$385.00 Average Price Allowed
By Medicare:
$76.96
HCPCS Code:99204 Description:Office/outpatient visit new Average Price:$460.00 Average Price Allowed
By Medicare:
$175.15
HCPCS Code:20552 Description:Inj trigger point 1/2 muscl Average Price:$279.00 Average Price Allowed
By Medicare:
$54.59
HCPCS Code:99203 Description:Office/outpatient visit new Average Price:$307.96 Average Price Allowed
By Medicare:
$114.41
HCPCS Code:99233 Description:Subsequent hospital care Average Price:$292.00 Average Price Allowed
By Medicare:
$107.94
HCPCS Code:99214 Description:Office/outpatient visit est Average Price:$295.00 Average Price Allowed
By Medicare:
$111.89
HCPCS Code:01996 Description:Hosp manage cont drug admin Average Price:$216.00 Average Price Allowed
By Medicare:
$72.54
HCPCS Code:99232 Description:Subsequent hospital care Average Price:$213.31 Average Price Allowed
By Medicare:
$75.14
HCPCS Code:99213 Description:Office/outpatient visit est Average Price:$195.00 Average Price Allowed
By Medicare:
$75.80
HCPCS Code:99231 Description:Subsequent hospital care Average Price:$116.00 Average Price Allowed
By Medicare:
$41.27
HCPCS Code:J1040 Description:Methylprednisolone 80 MG inj Average Price:$38.00 Average Price Allowed
By Medicare:
$6.68
HCPCS Code:J3301 Description:Triamcinolone acet inj NOS Average Price:$6.00 Average Price Allowed
By Medicare:
$1.69
HCPCS Code:Q9965 Description:LOCM 100-199mg/ml iodine,1ml Average Price:$5.00 Average Price Allowed
By Medicare:
$0.93

HCPCS Code Definitions

J3301
Injection, triamcinolone acetonide, not otherwise specified, 10 mg
J1040
Injection, methylprednisolone acetate, 80 mg
20610
Arthrocentesis, aspiration and/or injection; major joint or bursa (eg, shoulder, hip, knee joint, subacromial bursa)
20552
Injection(s); single or multiple trigger point(s), 1 or 2 muscle(s)
62310
Injection(s), of diagnostic or therapeutic substance(s) (including anesthetic, antispasmodic, opioid, steroid, other solution), not including neurolytic substances, including needle or catheter placement, includes contrast for localization when performed, epidural or subarachnoid; cervical or thoracic
99291
Critical care, evaluation and management of the critically ill or critically injured patient; first 30-74 minutes
99204
Office or other outpatient visit for the evaluation and management of a new patient, which requires these 3 key components: A comprehensive history; A comprehensive examination; Medical decision making of moderate complexity. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the presenting problem(s) are of moderate to high severity. Typically, 45 minutes are spent face-to-face with the patient and/or family.
77003
Fluoroscopic guidance and localization of needle or catheter tip for spine or paraspinous diagnostic or therapeutic injection procedures (epidural or subarachnoid)
62311
Injection(s), of diagnostic or therapeutic substance(s) (including anesthetic, antispasmodic, opioid, steroid, other solution), not including neurolytic substances, including needle or catheter placement, includes contrast for localization when performed, epidural or subarachnoid; lumbar or sacral (caudal)
64483
Injection(s), anesthetic agent and/or steroid, transforaminal epidural, with imaging guidance (fluoroscopy or CT); lumbar or sacral, single level
64448
Injection, anesthetic agent; femoral nerve, continuous infusion by catheter (including catheter placement)
99203
Office or other outpatient visit for the evaluation and management of a new patient, which requires these 3 key components: A detailed history; A detailed examination; Medical decision making of low complexity. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the presenting problem(s) are of moderate severity. Typically, 30 minutes are spent face-to-face with the patient and/or family.
64445
Injection, anesthetic agent; sciatic nerve, single
99232
Subsequent hospital care, per day, for the evaluation and management of a patient, which requires at least 2 of these 3 key components: An expanded problem focused interval history; An expanded problem focused examination; Medical decision making of moderate complexity. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the patient is responding inadequately to therapy or has developed a minor complication. Typically, 25 minutes are spent at the bedside and on the patient's hospital floor or unit.
99233
Subsequent hospital care, per day, for the evaluation and management of a patient, which requires at least 2 of these 3 key components: A detailed interval history; A detailed examination; Medical decision making of high complexity. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the patient is unstable or has developed a significant complication or a significant new problem. Typically, 35 minutes are spent at the bedside and on the patient's hospital floor or unit.
99214
Office or other outpatient visit for the evaluation and management of an established patient, which requires at least 2 of these 3 key components: A detailed history; A detailed examination; Medical decision making of moderate complexity. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the presenting problem(s) are of moderate to high severity. Typically, 25 minutes are spent face-to-face with the patient and/or family.
99213
Office or other outpatient visit for the evaluation and management of an established patient, which requires at least 2 of these 3 key components: An expanded problem focused history; An expanded problem focused examination; Medical decision making of low complexity. Counseling and coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the presenting problem(s) are of low to moderate severity. Typically, 15 minutes are spent face-to-face with the patient and/or family.
99231
Subsequent hospital care, per day, for the evaluation and management of a patient, which requires at least 2 of these 3 key components: A problem focused interval history; A problem focused examination; Medical decision making that is straightforward or of low complexity. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the patient is stable, recovering or improving. Typically, 15 minutes are spent at the bedside and on the patient's hospital floor or unit.
Q9965
Low osmolar contrast material, 100-199 mg/ml iodine concentration, per ml

Medical Malpractice Cases

None Found

Medical Board Sanctions

None Found

Referrals

NPI
Doctor Name
Specialty
Count
1962567792
Orthopedic Surgery
358
1891740148
Orthopedic Surgery
331
1043261555
Emergency Medicine
267
1124041603
Neurosurgery
255
1528047487
Diagnostic Radiology
229
1275586554
Physical Medicine And Rehabilitation
140
1114958121
Cardiovascular Disease (Cardiology)
123
1073558276
Cardiovascular Disease (Cardiology)
118
1184614711
Cardiovascular Disease (Cardiology)
116
1710943220
Pathology
85
*These referrals represent the top 10 that Dr. Malik has made to other doctors

Publications

Efficacy of Pregabalin in the Treatment of Radicular Pain: Results of a Controlled Trial. - Anesthesiology and pain medicine
Pregabalin is commonly used to treat patients with various neuropathic pain syndromes.The purpose of the present study was to evaluate the efficacy of pregabalin in patients with lumbar or cervical radicular pain.A prospective, randomized, double-blind trial was conducted in 39 patients with lumbar and cervical radicular pain, who received 3 weeks of either pregabalin (n = 10) or placebo (n = 9) treatment. Baseline pain and disability were evaluated before the treatment and were re-evaluated, along with overall patient satisfaction, after the 3 weeks of treatment.Data on 19 of the 39 patients recruited were available for analysis. No statistically significant differences in the pain, disability, and patient satisfaction scores were found between the groups. When the individual patient scores were assessed, the placebo treatment was found to be efficacious in 4 of the 9 patients and pregabalin was effective in 2 of the 10 patients, but the difference was not statistically significant (P = 0.350).The present data do not suggest that pregabalin is more efficacious than placebo in the treatment of lumbar and cervical radicular pain. However, the small sample size of this study may have affected the ability to detect such a difference.
Disease-modifying Antirheumatic Drugs for the Treatment of Low Back Pain: A Systematic Review of the Literature. - Pain practice : the official journal of World Institute of Pain
Low back pain (LBP) is a common source of pain and disability, which has an enormous adverse impact on affected individuals and the community as a whole. The etiologies of LBP are protean and local inflammation contributes to the majority of these processes. Although an array of potent disease-modifying anti-rheumatic drugs (DMARDs), which are typically anti-inflammatory in character, have become clinically available only corticosteroids are routinely used for the treatment of LBP. To further investigate this potentially underutilized therapy, we reviewed the available literature to determine the role of DMARDs in the treatment of LBP. Our results show that the current DMARD use for LBP is indeed limited in scope and is characterized by isolated use and empiric selection of drugs from a range of available DMARDs. Moreover, the dose, frequency, and route of drug administration are selected arbitrarily and deviated from treatment protocols proposed for the management of other inflammatory conditions. The literature published on this topic is of low quality, and the results of the reviewed trials were inconclusive or demonstrated only short-term efficacy of these medications. Based on the findings of this review, we recommend that the future DMARD use for LBP is initially limited to patients with debilitating disease who are unresponsive to conventional treatments, and the criteria for drug selection and routes of drug administration are clearly defined and may be modeled after treatment protocols for other inflammatory conditions.© 2015 World Institute of Pain.
Chronic kidney disease (CKD) treatment burden among low-income primary care patients. - Chronic illness
This study explored the self-management strategies and treatment burden experienced by low-income US primary care patients with chronic kidney disease.Semi-structured interviews were conducted with 34 patients from two primary care practices on Buffalo's East Side, a low-income community. Qualitative analysis was undertaken using an inductive thematic content analysis approach. We applied normalization process theory (NPT) to the concept of treatment burden to interpret and categorize our findings.The sample was predominantly African-American (79%) and female (59%). Most patients (79%) had a diagnosis of stage 3 CKD. Four major themes were identified corresponding to NPT and treatment burden: (1) coherence--making sense of CKD; (2) cognitive participation--enlisting support and organizing personal resources; (3) collective action--self-management work; and (4) reflexive monitoring--further refining chronic illness self-care in the context of CKD. For each component, we identified barriers hindering patients' ability to accomplish the necessary tasks.Our findings highlight the substantial treatment burden faced by inner-city primary care patients self-managing CKD in combination with other chronic illnesses. Health care providers' awareness of treatment burden can inform the development of person-centered care plans that can help patients to better manage their chronic illnesses.© The Author(s) 2014.
Steroid-resistant nephrotic syndrome: impact of genetic testing. - Annals of Saudi medicine
Mutations in several genes are known to cause steroid-resistant nephrotic syndome (SRNS), most commonly in NPHS1, NPHS2, and WT1. Our aims were to determine the frequency of mutations in these genes in children with SRNS, the response of patients with SRNS to various immunosuppressants, and the disease outcome, and to review the predictive value of genetic testing and renal biopsy result.A retrospective review was performed of the medical records for all children with SRNS who were treated and followed-up in the Pediatric Nephrology Unit of King Abdulaziz University Hospital (KAUH), Jeddah, Saudi Arabia from 2002-2012.We retrospectively reviewed the medical records of children above 1 year of age, who presented with SRNS to KAUH, Jeddah, Saudi Arabia, in the 10-year interval from 2002-2012 and for whom the results of genetic testing for NPHS1, NPHS2, and WT1 were available. We compared the clinical phenotype, including response to treatment and renal outcome to genotype data.We identified 44 children with a clinical diagnosis of SRNS in whom results of genetic testing were available. Presumably disease-causing mutations were detected in 5 children (11.4%) of which 3 (6.8%) had NPHS2 mutation and 2 (4.5%) had NPHS1 mutation. Renal biopsy revealed minimal change disease (MCD) or variants in 17 children, focal segmental glomerulosclerosis (FSGS) in 23 children, membranoproliferative changes (MPGN) in 2 children, and IgA nephropathy in another 2 children. Children with MCD on biopsy were more likely to respond to treatment than those with FSGS. None of those with an identified genetic cause showed any response to treatment.The frequency of identified disease-causing mutations in children older than 1 year with SRNS presented to KAUH was 11.4%, and these patients showed no response to treatment. Initial testing for gene mutation in children with SRNS may obviate the need for biopsy, and the use of immunosuppressive treatment in children with disease due to NPHS1 or NPHS2 mutations. Renal biopsy was useful in predicting response in those without genetic mutations.
Diagnostic criteria and treatment of discogenic pain: a systematic review of recent clinical literature. - The spine journal : official journal of the North American Spine Society
Pain innate to intervertebral disc, often referred to as discogenic pain, is suspected by some authors to be the major source of chronic low back and neck pain. Current management of suspected discogenic pain lacks standardized diagnosis, treatment, and terminology.In an attempt to determine whether patterns existed that may facilitate standardization of care, we sought to analyze the terminologies used and the various modes of diagnosis and treatment of suspected discogenic pain.A systematic review of the recent literature.A Medline search was performed using the terms degenerative disc disease, discogenic pain, internal disc disruption while using the limits of human studies, English language, and clinical trials, for the last 10 years. The search led to a total of 149 distinct citations, of which 53 articles, where the intervertebral disc itself was considered the principal source of patient's pain and was the main target of the treatment, were retained for further analysis.The results of this review confirm and help quantify the significant differences that existed in the terminology and all the areas of diagnosis and treatment of presumed discogenic pain.Our findings show that suspected discogenic pain, despite its extensive affirmation in the literature and enormous resources regularly devoted to it, currently lacks clear diagnostic criteria and uniform treatment or terminology.Copyright © 2013 Elsevier Inc. All rights reserved.
Prescription patterns of pain medicine physicians. - Pain practice : the official journal of World Institute of Pain
Our study surveyed physician members of 3 American pain societies to determine prescription patterns and whether these practices reflect current expert opinion.We sent 3 mailings to 2938 physicians from January 2010 to January 2011. The questionnaire contained 49 questions on topics related to opioids, antidepressants, anticonvulsants, and preferences for the different pain syndromes.A total of 474 physicians responded, representing a 16% return. Seventy-two percent ask patients to sign an opioid agreement, 59% order random urine drug testing, 13% wait until the dose of methadone is between 100 and 150 mg before converting the drug to another opioid, and 85% do not think there is a maximum dose of opioids with respect to driving. Most responders prescribe codeine to Caucasians and Asians. While 42% stated that the maximum daily dose of acetaminophen is 3000 mg, 75% would decrease the dose in patients who are moderate or heavy drinkers. Fifty-four percent do not order an ECG at all when prescribing tricyclic antidepressants.The responses pertaining to opioid agreements, urine drug testing, acetaminophen, and treatment for neuropathic pain are reassuring in that they prevent misuse and abuse of opioids, prevent acetaminophen-induced hepatotoxicity, and reflect evidence-based treatments. However, we identified gaps in knowledge, including the prescription of codeine in certain populations and the use of electrocardiogram in patients on antidepressants. Further education of physicians who treat chronic pain pharmacologically is warranted.© 2012 The Authors Pain Practice © 2012 World Institute of Pain.
Bone marrow infection with Mycobacterium fortuitum in a diabetic patient. - Journal of the College of Physicians and Surgeons--Pakistan : JCPSP
Incidence and prevalence of Mycobacterium fortuitum infection vary greatly by location and death is very rare except in disseminated disease in immunocompromised individuals. We present what we believe is the first case of bone marrow infection with Mycobacterium fortuitum in an HIV negative patient. Bone marrow examination revealed presence of numerous acid fast bacilli which were confirmed as Mycobacterium fortuitum on culture and by molecular analysis. Patient was managed successfully with amikacin and ciprofloxacin.
Scalene muscle injections for neurogenic thoracic outlet syndrome: case series. - Pain practice : the official journal of World Institute of Pain
Scalene muscle injections are used to confirm the diagnosis of neurogenic thoracic outlet syndrome and predict the response of patients to surgery. We performed a retrospective study to determine if relief of pain was related to brachial plexus blockade in these patients.We reviewed the charts of 12 patients who had anterior and middle scalene muscle injections, for neurogenic thoracic outlet syndrome, between April 2009 and September 2010. The injections were performed under ultrasound guidance wherein 2 to 5 mL of 0.25% bupivacaine was injected into the belly of the anterior and scalene muscles. The following were noted: (1) sites of preprocedure pain; (2) volume injected into each of the anterior and middle scalene muscles; (3) presence of numbness after injection; and (4) presence and duration of pain relief.All 12 patients had relief of their pain. Six of the twelve patients developed numbness, which ranged from blockade of the C4-5, C6-7, and C4-T1 dermatomes. In the patients who developed numbness, there was no relationship between the duration of numbness and the duration of pain relief or the location of numbness and the location of pain relief.The relief from scalene muscle injections in patients with neurogenic thoracic outlet syndrome is not related to blockade of the brachial plexus.© 2011 The Authors. Pain Practice © 2011 World Institute of Pain.
Water-cooled radiofrequency: a neuroablative or a neuromodulatory modality with broader applications? - Case reports in anesthesiology
We report the successful use of water-cooled radiofrequency where more traditional forms of neuroablation-conventional and pulsed radiofrequency-had failed to achieve adequate pain relief. We also discuss the mechanism of neural damage with water cooled radiofrequency and discuss why this technique may have a broader role in the management of a wide array of pain syndromes.
The use of a diagnostic wax set-up in aesthetic cases involving crown lengthening--a case report. - Dental update
Crown-lengthening surgery (CLS) consists of recontouring and repositioning the gingival margin as well as the alveolar crest. This technique results in the increase of the clinical crown height of teeth, which can consequently be advantageous in terms of improving retention and resistance, as well as aesthetics.The aim of this article is to demonstrate the uses of the diagnostic wax set-up and the subsequent production of surgical stents and templates to provide the patient with an initial intra-oral diagnostic mock-up for the process of obtaining consent, as well as acting as a useful guide for gingival and osseous recontouring in order to achieve a predictable, healthy and stable dento-gingival complex with pleasing aesthetics.The use of a well made diagnostic wax-up can provide valuable information to the dentist, laboratory, and patient which can be otherwise difficult to communicate.

Map & Directions

251 E Huron St Feinberg 5-520 Chicago, IL 60611
View Directions In Google Maps

Nearby Doctors

225 E Chicago Ave Neurosurgery
Chicago, IL 60611
312 274-4220
737 N Michigan Ave Suite 2240
Chicago, IL 60611
312 550-0140
737 N Michigan Ave Suite 2130
Chicago, IL 60611
312 401-1709
233 E Erie St
Chicago, IL 60611
312 370-0374
225 E Chicago Ave Box 24
Chicago, IL 60611
312 276-6340
251 E Huron St Galter 3-150
Chicago, IL 60611
312 262-2253
251 E Huron St Galter 3-150
Chicago, IL 60611
312 262-2253
251 E Huron St F5-704
Chicago, IL 60611
312 268-8132
251 E Huron St Feinberg 4-741G
Chicago, IL 60611
312 264-4415
250 E Superior St
Chicago, IL 60611
312 723-3970